Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Q2 revenue up 22% to $71.6M; net loss widens to $39.9M

Mixed Impact 4 of 5 earnings Written later

Adaptive Biotechnologies reported second quarter 2026 revenue of $71.6 million, up 22% from a year earlier, and raised its full-year 2026 MRD revenue guidance to $268 million to $278 million. The net loss widened to $39.9 million from $25.6 million, including a $23.7 million loss on the settlement of the OrbiMed Purchase Agreement, and Chief Scientific Officer Harlan Robins is moving to a strategic consultant role.

Key points

  • Q2 2026 revenue was $71.6 million; MRD revenue rose 33% to $66.2 million, while Immune Medicine revenue fell 40% to $5.4 million.
  • Net loss attributable to the company was $39.8 million, or $0.25 per share, versus $25.6 million, or $0.17 per share, a year earlier.
  • Full-year 2026 MRD revenue guidance rose to $268 million to $278 million from $260 million to $270 million; total operating expense guidance was narrowed to $350 million to $355 million from $350 million to $360 million.
  • On July 24, 2026, Chief Scientific Officer and co-founder Dr. Harlan Robins decided to move to a strategic consultant role; a consulting agreement is expected.

The filing

CompanyAdaptive Biotechnologies Corp (ADPT)
Form8-K, current report
Filed with the SECJul 29, 2026, 4:15 PM ET
Accession number0001193125-26-323753

Items reported: 2.02 Results of Operations5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.